SOLICITATION NOTICE
65 -- Affymetrix Genome-Wide Human SNP Array 5.0 Chips
- Notice Date
- 8/2/2010
- Notice Type
- Presolicitation
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100157-KM
- Archive Date
- 9/2/2010
- Point of Contact
- Karri L. Mares, Phone: 3014357774, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
maresk@mail.nih.gov, cr214i@nih.gov
(maresk@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852, UNITED STATES Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Epidemiology Branch (EB) plans to procure on a sole source basis the acquisition of Affymetrix Genome-Wide Human SNP Array 5.0 Chips from Affymetrix, Inc., 3420 Central Expressway, Santa Clara, CA 95051. The supplies and services herein are being procured in accordance with the simplified acquisition procedures as authorized by FAR Part 13.106 (b)(1). The North American Industry Classification System code is 325413 and the business size standard is 500 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The delivery date shall be 30 days from date of award. The acquisition of chips and reagents is an integral part of the Barrett's Esophagus Early Detection Study, an ongoing collaboration between the NCI and the National Naval Medical Center in Bethesda which was initiated in 2006. The primary goal of this project is to identify a practical blood-based biomarker(s) that can be used as a screening test to determine who has Barrett's esophagus and who does not. Finding such biomarkers will permit the collaborative study group to screen populations, identify persons at particularly high risk, and target them for prevention strategies. The current project will test DNA in Barrett's esophagus tissue, normal gastric, and normal squamous esophageal tissues from ~50 Barrett's patients, and normal gastric and normal squamous esophageal tissues from ~50 non-Barrett's comparison patients. These patients/samples will be tested for genome-wide DNA genetic variation (loss of heterozygosity and copy number variation) and genome-wide epigenetic changes (methylation status); the new data will be compared with previously-obtained RNA expression array data on the same patients/samples. This collaborative group has previously studied esophageal squamous cell carcinoma using the same Affymetrix Genome-Wide Human SNP Array 5.0 that will be purchased for use in the current analysis; comparability of the new data with previously-generated data is critical to the integrity of the research. Affymetrix is a worldwide leader in genome-wide technology and the NCI has utilized the Affymetrix platforms over the course of the past five years. Specifically, the NCI's Advanced Technology Center currently utilizes the Affymetrix GeneChip Scanner and software to read such chips, as well as the Affymetrix GeneChip Fluidic Station. Extensive development of methods to clean and analyze the data, and managing the enormous volume of data acquired from each chip and experiment could not be duplicated without compromising the integrity and continuity of the ongoing scientific research. Accordingly, it is essential that the new DNA genetic variation and epigenetic data generated from this project be compatible with the enormous amount of similar expression data that have been generated by this laboratory from studies to date. Such data have come from Affymetrix Genome-Wide Human SNP Arrays that will be purchased under this acquisition. This notice is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 11:00 AM EST, on August 18, 2010. For further information, please contact Karri Mares, Contract Specialist via electronic mail at maresk@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed or emailed capability statements will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA). Reference: NCI-100157-KM on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100157-KM/listing.html)
- Record
- SN02225424-W 20100804/100802235003-82bb0d5427ebd9d76519d735a1892e61 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |